4550
K.V. Zavyalov et al. / Tetrahedron 69 (2013) 4546e4551
from azirine 1a (103 mg, 0.71 mmol) and diazo compound 2a
(112 mg, 0.71 mmol) as a colorless solid (50 mg, 26%). Mp 90e91ꢀS
(hexane/Et2O); Rf (33% EtOAc/hexane) 0.33; IR (KBr): 3089, 2966,
167.9 (C-4). HRMS (ESI-TOF, [MþH]þ): calcd for C15H16NO5,
290.1023; found 290.1027.
1756, 1632, 1580, 1534 cmꢁ1 1H NMR (300 MHz, CDCl3):
d
3.90 (s,
4.3.7. Dimethyl 4,5-diphenyl-2H-1,3-oxazine-2,2-dicarboxylate (5f).
Compound 5f was prepared according to the general procedure
from azirine 1f (100 mg, 0.45 mmol) and diazo compound 2a
(107 mg, 0.68 mmol) as a light yellow solid (49 mg, 31%). Mp
71e74 ꢀC (hexane/Et2O); Rf (33% EtOAc/hexane) 0.39; IR (KBr):
6H, 2CH3O), 6.15 (d, 1H, J¼5.8 Hz, H-5), 7.14 (d, 1H, J¼5.8 Hz, H-6),
7.42e7.53 (m, 3H, ArH), 7.88e7.90 (m, 2H, ArH). 13C NMR (75 MHz,
CDCl3): d 53.6 (2C, CH3O), 90.7 (C-2), 100.4 (C-5), 127.1, 128.6, 131.5,
135.3 (Ar), 152.5 (C-6), 161.8 (C]O), 166.4 (C-4). HRMS (ESI-TOF,
[MþH]þ): calcd for C14H14NO5, 276.0866; found 276.0854. Anal.
Calcd for C14H13NO5: C, 61.09; H, 4.76; N, 5.09. Found: C, 61.06; H,
4.60; N, 5.34. Crystal data: C14H13NO5, M¼275.25, orthorhombic,
2960, 1765, 1635, 1535 cmꢁ1
.
1H NMR (300 MHz, CDCl3):
d
3.93
(s, 6H, 2CH3O), 6.98e7.02 (m, 2H, ArH), 7.19e7.39 (m, 9H, H-6, ArH).
13C NMR (75 MHz, CDCl3):
53.7 (2C, CH3O), 90.3 (C-2), 119.1 (C-5),
d
3
ꢀ
ꢀ
a¼6.0659(3), b¼7.6566(4), c¼28.7710(15) A, V¼1336.25(12) A ,
127.5, 127.8, 128.2, 128.5, 129.2, 130.1, 133.7, 136.0 (Ar), 149.9 (C-6),
165.9 (C-4), 166.4 (2C, C]O). HRMS (ESI-TOF, [MþH]þ): calcd for
C20H18NO5, 352.1179; found 352.1185.
T¼120 K, space group P212121, Z¼4,
m(MoK
a
)¼0.105 mmꢁ1, 14,210
reflections measured, 1987 unique (Rint¼0.0691) were used in all
calculations. The final R1 was 0.0447 (1519>2
s
(I)), wR2¼0.1150
(all data).
4.3.8. Dimethyl (E)-2-[(4-oxo-3-phenylpent-2-en-2-yl)imino]malo-
nate (E-4g) and dimethyl 4,6-dimethyl-5-phenyl-2H-1,3-oxazine-2,2-
dicarboxylate (5g). Azadiene E-4g (16 mg, 9%) and oxazine 5g
(77 mg, 44%) were prepared according to the general procedure from
azirine 1g (100 mg, 0.58 mmol) and diazo compound 2a (131 mg,
0.83 mmol). Compound E-4g, orange solid, mp 54e55 ꢀC (hexane/
4.3.3. Dimethyl 4-(4-methoxyphenyl)-2H-1,3-oxazine-2,2-dicarboxy-
late (5b). Compound 5b was prepared according to the general
procedure from azirine 1b (105 mg, 0.6 mmol) and diazo com-
pound 2a (142 mg, 1.2 mmol) as a light yellow solid (69 mg, 23%).
Mp 81e83 ꢀC (hexane/Et2O); Rf (50% EtOAc/hexane) 0.44; IR
Et2O).1H NMR (300 MHz, CDCl3):
3.82 (s, 6H, 2CH3O), 7.07e7.10 (m, 2H, ArH), 7.28e7.35 (m, 3H, ArH).
13C NMR (75 MHz, CDCl3):
18.9 (CH3), 31.1 (CH3), 53.1 (2C, CH3O),
d 2.03 (s, 3H, CH3), 2.34 (s, 3H, CH3),
(KBr): 2963, 1764, 1633, 1600 cmꢁ1 1H NMR (300 MHz, CDCl3):
.
d
3.85 (s, 3H, CH3O), 3.89 (s, 6H, CH3O), 6.12 (s, 1H, J¼5.8 Hz, H-5),
d
6.93 (d, 2H, J¼8.7 Hz, ArH), 7.11 (d, 1H, J¼5.8 Hz, H-6), 7.86 (d, 2H,
100.1 (C-3), 121.4 (C-2), 127.6, 128.5, 129.7, 136.2 (Ar), 148.5 (C]N),
153.1 (2C, C]O), 200.0 (C]O). Crystal data: C16H17NO5, M¼303.3,
J¼8.7 Hz, ArH). 13C NMR (75 MHz, CDCl3):
d 53.6 (2C, CH3O), 55.4
ꢀ
(CH3O), 90.7 (C-2), 100.3 (C-5), 113.8, 127.7, 128.9 (Ar), 152.2 (C-6),
160.8 (Ar), 162.4 (C-4), 166.6 (2C, C]O). HRMS (ESI-TOF,
[MþH]þ): calcd for C15H16NO6, 306.0972; found 306.0968. Anal.
Calcd for C15H15NO6: C, 59.01; H, 4.95; N, 4.59. Found: C, 59.02;
H, 4.80; N, 4.76.
triclinic, space group P-1, a¼8.2133(3), b¼8.ꢀ6001(3), c¼12.2957(4) A,
3
ꢀ
a
¼97.967(1),
b
¼100.663(1),
g
¼113.603(1) , V¼759.98(5) A , Z¼2,
T¼120 K,
m
(MoK
a
)¼0.099 mmꢁ1, 12,704 reflections measured, 4048
unique (Rint¼0.0315) were used in all calculations. The final R1 was
0.0398 (3286>2s(I)) and wR2 was 0.1173 (all data).
Compound 5g, colorless solid, mp 103e104 ꢀC (hexane/Et2O); Rf
4.3.4. Dimethyl 4-(4-chlorophenyl)-2H-1,3-oxazine-2,2-dicarboxy-
late (5c). Compound 5c was prepared according to the general
procedure from azirine 1c (108 mg, 0.6 mmol) and diazo compound
2a (95 mg, 0.6 mmol) as a light yellow oil (78 mg, 42%). 1H NMR
(50% EtOAc/hexane) 0.37; IR (KBr): 2958, 2924, 2852, 1749,
1658 cmꢁ1
.
1H NMR (300 MHz, CDCl3):
d
1.90 (s, 3H, CH3), 1.91
(s, 3H, CH3), 3.90 (s, 6H, CH3O), 7.07e7.10 (m, 2H, ArH), 7.31e7.41
(m, 3H, ArH). 13C NMR (75 MHz, CDCl3):
17.1 (CH3), 23.6 (CH3),
d
(300 MHz, CDCl3):
d
3.90 (s, 6H, 2CH3O), 6.09 (d, 1H, J¼5.8 Hz, H-5),
53.5 (2C, CH3O), 90.2 (C-2), 115.9 (C-5), 127.8, 128.6, 130.2, 134.3
(Ar), 158.2 (C-6), 166.7 (C-4), 166.9 (2C, C]O). HRMS (ESI-TOF,
[MþH]þ): calcd for C16H18NO5, 304.1179; found 304.1199.
7.14 (d, 1H, J¼5.8 Hz, H-6), 7.41 (d, 2H, J¼8.5 Hz, ArH), 7.83 (d, 2H,
J¼8.5 Hz, ArH). 13C NMR (75 MHz, CDCl3):
d 53.7 (2C, CH3O), 90.6
(C-2), 100.0 (C-5), 128.5, 128.8, 133.6, 137.8 (Ar), 152.8 (C-6), 160.8
(C-4), 166.2 (2C, C]O). HRMS (ESI-TOF, [MþH]þ): calcd for
C14H13NO5Cl, 310.0477; found 310.0471.
4.3.9. Ethyl 4-formyl-3-methyl-5-(4-methoxyphenyl)-2-oxo-2,3-
dihydro-1H-pyrrole-3-carboxylate (10). Compound 10 (143 mg,
55%) was prepared according to the general procedure from azirine
1d (150 mg, 0.86 mmol) and diazo compound 2b (334 mg,
2.14 mmol) as a light yellow solid; mp 135e137 ꢀC (Et2O); Rf (33%
EtOAc/hexane) 0.35; IR (KBr): 3176, 2981, 2940, 1750, 1713, 1644,
4.3.5. Dimethyl 4-(4-methylphenyl)-2H-1,3-oxazine-2,2-dicarboxy-
late (5d). Compound 5d was prepared according to the general
procedure from azirine 1d (70 mg, 0.44 mmol) and diazo com-
pound 2a (70 mg, 0.44 mmol) as a light yellow solid (45 mg, 35%).
Mp 129e131 ꢀC (Et2O/hexane); Rf (33% EtOAc/hexane) 0.36; IR
(KBr): 3086, 2966, 1769, 1754, 1629, 1530 cmꢁ1. 1H NMR (300 MHz,
1602 cmꢁ1. 1H NMR (300 MHz, CDCl3):
d
1.21 (t, 3H, J¼7.3 Hz, CH3),
1.72 (s, 3H, CH3), 3.91 (s, 3H, CH3O), 4.12e4.27 (m, 2H, CH2), 7.06
(d, 2H, J¼8.7 Hz, ArH), 7.60 (d, 2H, J¼8.7 Hz, ArH), 9.26 (s, 1H, NH),
CDCl3):
d
2.40 (s, 3H, CH3), 3.89 (s, 6H, 2CH3O), 6.13 (d, 1H, J¼5.8 Hz,
9.64 (s, 1H, HC]O). 13C NMR (75 MHz, CDCl3):
d 13.9 (CH3), 18.8
H-5), 7.12 (d, 1H, J¼5.8 Hz, H-6), 7.24 (d, 2H, J¼8.0 Hz, ArH), 7.79 (d,
(CH3), 55.6 (CH3O), 56.7 (C-3), 62.0 (CH2), 114.8, 119.3, 121.2, 130.4,
157.1, 162.7, 167.6, 178.0, 184.0 (Ar, NC]O, OC]O, HC]O). HRMS
(ESI-TOF, [MþK]þ): calcd for C16H17NO5K, 342.0738; found
342.0757. Anal. Calcd for C16H17NO5: C, 63.36; H, 5.65; N, 4.62.
Found: C, 62.96; H, 5.49; N, 4.76.
2H, J¼8.0 Hz, ArH). 13C NMR (75 MHz, CDCl3):
d 21.4 (CH3), 53.6 (2C,
CH3O), 90.7 (C-2), 100.4 (C-5), 127.1, 129.2, 132.5, 142.0 (Ar), 152.3
(C-6), 161.5 (C-4), 166.5 (2C, C]O). HRMS (ESI-TOF, [MþH]þ): calcd
for C15H16NO5, 290.1023; found 290.1029. Anal. Calcd for
C15H15NO5: C, 62.28; H, 5.23; N, 4.84. Found: C, 61.99; H, 5.06; N,
5.08.
4.3.10. 5-(Ethoxycarbonyl)-2-(4-methoxyphenyl)-4-phenyl-1H-pyr-
role-3-carboxylic acid (12). Compound 12 (25 mg, 12%) was pre-
pared according to the general procedure from azirine 1d (100 mg,
0.57 mmol) and diazo compound 2c (311 mg, 1.43 mmol) as a light
yellow solid; mp 233e235 ꢀC (Et2O); Rf (33% EtOAc/hexane) 0.43; IR
(KBr): 3279, 2988,1661, 1612,1561 cmꢁ1. 1H NMR (300 MHz, DMSO-
4.3.6. Dimethyl 5-methyl-4-phenyl-2H-1,3-oxazine-2,2-dicarboxy-
late (5e). Compound 5e was prepared according to the general
procedure from azirine 1e (100 mg, 0.63 mmol) and diazo com-
pound 2a (100 mg, 0.63 mmol) as a light yellow oil (30 mg, 17%). 1H
NMR (300 MHz, CDCl3):
d
1.73 (d, 3H, J¼1.5 Hz, CH3), 3.89 (s, 6H,
d6):
d
1.02 (t, 3H, J¼6.9 Hz, CH3), 3.81 (s, 3H, CH3O), 4.04 (q, 2H,
3CH3O), 6.87 (q,1H, J¼1.5 Hz, H-6), 7.42e7.51 (m, 5H, ArH). 13C NMR
J¼6.9 Hz, CH2), 7.00 (d, 2H, J¼8.7 Hz, ArH), 7.29 (s, 5H, ArH), 7.52 (d,
(75 MHz, CDCl3):
d 14.1 (CH3), 53.6 (2C, CH3O), 90.0 (C-2), 111.0
2H, J¼8.7 Hz, ArH), 11.93 (s, 1H, NH), 12.23 (s, 1H, CO2H). 13C NMR
(C-5), 128.0, 128.2, 129.8, 136.6 (Ar), 148.0 (C-6), 166.6 (2C, C]O),
(75 MHz, DMSO-d6): d 14.7 (CH3), 56.1 (CH3O), 60.4 (CH2),114.1,115.8